The Surface Issue #7, October 2021 edition, was sent to all PSOLVE+ members by email on Tuesday, Sep 28, and can be accessed online here. This edition covers:
Concomitant PsA and PsO results from the EXCEED study
Risk of drug exposure in PsO patients on COVID-19 outcomes in France
Treatment of PsO and the natural history of PsA
PASI-HD – a solution for BSA <10%
Survey on the potential impact of a biomarker patch in PsO treatment selection
This video series was developed by a faculty of Canadian dermatologists from across Canada as part of the C2 Dermatology: Connect & Collaborate learning program, under the supervision of Dr. Simon Nigen and Dr. Vimal Prajapati. View all AAD C2 Dermatology videos at psolve.org/c2-derm.
In this Video #4, Dr. Michael Cecchini from Richmond Hill, Ontario, presents a 12-minute video update from the 2021 AAD VMX.
What new options are emerging in the treatment landscape for psoriasis?
How should we manage biologic therapies in patients with psoriasis and obesity?
Are the current treatment approaches for pediatric psoriasis patients sufficient?
Can children with psoriasis be safely treated with biologic therapies?
In compliance with Innovative Medicines Canada, this program is for Healthcare Professionals only, and is supported by Novartis Pharmaceuticals Canada.
Vous êtes convié(e)s à visionner les Modules vidéos de microapprentissage extraits du programme C2 Dermatology (Connect & Collaborate) Proceedings de l’American Academy of Dermatology Association Virtual Meeting Experience 2021 sous la supervision de Simon Nigen, MD, FRCPC (Montréal, QC) et de Vimal H. Prajapati, MD, FRCPC, FAAD (Calgary, AB). Au cours des prochaines semaines, nous mettrons en ligne les différents Modules selon le calendrier joint: psolve.org/c2-derm
Dans cette vidéo n° 4, le Dr Michael Cecchini (Richmond Hill, Ontario) présente un résumé de sessions tirées du congrès virtuel de l’AAD 2021.
This video series was developed by a faculty of Canadian dermatologists from across Canada as part of the C2 Dermatology: Connect & Collaborate learning program, under the supervision of Dr. Simon Nigen and Dr. Vimal Prajapati. View all AAD C2 Dermatology videos at psolve.org/c2-derm.
In this Video #3, Dr. Toni Burbidge from Calgary, Alberta, presents a 17-minute video update from the 2021 AAD VMX.
Does the mechanism of action of drugs targeting the IL-23 or IL-17A pathway explain differences in their clinical efficacy?
What are the cardiovascular benefits of biologic therapies vs.non-biologic therapies?
What guidance is there about the management of psoriatic disease?
How do you select psoriasis therapies in a complex landscape?
In compliance with Innovative Medicines Canada, this program is for Healthcare Professionals only, and is supported by Novartis Pharmaceuticals Canada.
Vous êtes convié(e)s à visionner les Modules vidéos de microapprentissage extraits du programme C2 Dermatology (Connect & Collaborate) Proceedings de l’American Academy of Dermatology Association Virtual Meeting Experience 2021 sous la supervision de Simon Nigen, MD, FRCPC (Montréal, QC) et de Vimal H. Prajapati, MD, FRCPC, FAAD (Calgary, AB). Au cours des prochaines semaines, nous mettrons en ligne les différents Modules selon le calendrier joint: psolve.org/c2-derm
Dans cette vidéo n° 3, la Dre Toni Burbidge (Calgary, Alberta) présente un résumé de sessions tirées du congrès virtuel de l’AAD 2021.
This video series was developed by a faculty of Canadian dermatologists from across Canada as part of the C2 Dermatology: Connect & Collaborate learning program, under the supervision of Dr. Simon Nigen and Dr. Vimal Prajapati. View all AAD C2 Dermatology videos at psolve.org/c2-derm.
In this Video #2, Dr. Lawrence Haiducu from Maple Ridge, BC, presents an 8-minute video update from the 2021 AAD VMX.
Should we consider biologic therapies for the treatment of mild-to-moderate psoriasis?
How do we manage psoriatic disease in the context of comorbidities or COVID?
What is the impact of patient-reported outcomes on treatment selection in psoriatic disease?
What evidence is there to guide our selection of a biologic therapy in difficult-to-treat areas?
In compliance with Innovative Medicines Canada, this program is for Healthcare Professionals only, and is supported by Novartis Pharmaceuticals Canada.
Vous êtes convié(e)s à visionner les Modules vidéos de microapprentissage extraits du programme C2 Dermatology (Connect & Collaborate) Proceedings de l’American Academy of Dermatology Association Virtual Meeting Experience 2021 sous la supervision de Simon Nigen, MD, FRCPC (Montréal, QC) et de Vimal H. Prajapati, MD, FRCPC, FAAD (Calgary, AB). Au cours des prochaines semaines, nous mettrons en ligne les différents Modules selon le calendrier joint: psolve.org/c2-derm
Dans cette vidéo n° 2, le Dr Lawrence Haiducu (Maple Ridge, BC) présente un résumé de sessions tirées du congrès virtuel de l’AAD 2021.
This video series was developed by a faculty of Canadian dermatologists from across Canada as part of the C2 Dermatology: Connect & Collaborate learning program, under the supervision of Dr. Simon Nigen and Dr. Vimal Prajapati. View all AAD C2 Dermatology videos at psolve.org/c2-derm.
In this Video #1, Dr. Farheen Mussani from Stoney Creek, Ontario, presents a 9-minute video update from the 2021 American Academy of Dermatology (AAD) Virtual Meeting Experience.
Why should we pay attention to the burden of disease in all patients?
What treatment regimen to consider in the management of palmoplantar psoriasis?
What does real-world data mean for your practice?
Why should we discuss the patient’s perspective around ‘remission’?
In compliance with Innovative Medicines Canada, this program is for Healthcare Professionals only, and is supported by Novartis Pharmaceuticals Canada.
Vous êtes convié(e)s à visionner les Modules vidéos de microapprentissage extraits du programme C2 Dermatology (Connect & Collaborate) Proceedings de l’American Academy of Dermatology Association Virtual Meeting Experience 2021 sous la supervision de Simon Nigen, MD, FRCPC (Montréal, QC) et de Vimal H. Prajapati, MD, FRCPC, FAAD (Calgary, AB). Au cours des prochaines semaines, nous mettrons en ligne les différents Modules selon le calendrier joint: psolve.org/c2-derm
Dans cette vidéo n° 1, le Dre Farheen Mussani (Stoney Creek, ON) présente une vidéo de 9 minutes de l’AAD VMX 2021.
The Surface Issue #6, August 2021 edition, was sent to all PSOLVE+ members by email on Monday, August 2, and can be accessed online here. This edition covers:
Predictors of methotrexate discontinuation in plaque psoriasis
Systematic review of predictive biomarkers for treatment response in psoriasis and psoriatic arthritis
Normalization of bone microarchitecture following anti-TNF treatment for PsA
Characterizing Degos disease by systematic review
Case report of cutaneous Emmonsia infection in a renal transplant recipient
Case report of atypical melanocytic nevi with segmental distribution
The Surface Issue #5, July 2021 edition, was sent to all PSOLVE+ members by email on Monday, July 5, and can be accessed online here. This edition covers:
Upadacitinib for biologic-refractory psoriatic arthritis
Urticaria disease activity during and after pregnancy
Case reports of paradoxical sarcoidosis in patients on anti-TNFs
Fixed drug eruption following two different antibiotics
The Surface Issue #2, April edition, was sent to all PSOLVE+ members by email on Monday, March 29, and can be accessed online here. This edition covers:
Vaccine literacy amongst patients with psoriasis
Pregnancy outcomes from the PSOLAR registry
Bimekizumab phase 3 results in moderate-to-severe plaque psoriasis
Targeting the IL-23/IL-17 pathway in plaque psoriasis
Compassionately addressing teratogenic risk factors in the transgender population
Real-world safety profile of acitretin in psoriasis patients
